Condition: Angelman Syndrome · Sponsor: MavriX Bio, LLC
The purpose of this study is to evaluate the safety and efficacy of MVX-220 gene therapy in children and adults with Angelman syndrome with UBE3A gene deletion, uniparental disomy, or imprinting center defect genotypes.
This description comes directly from the study's public registry record.
MavriX Bio, LLC · 978-538-8554 · info@mvxbio.com
Always discuss trial participation with your own doctor first.
| Cedars-Sinai Medical Center | Los Angeles, California, United States | Recruiting |
| Rush University Medical Center | Chicago, Illinois, United States | Recruiting |
| Boston Children's Hospital | Boston, Massachusetts, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07181837